Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial.
Petak I, Kamal M, Dirner A, Bieche I, Doczi R, Mariani O, Filotas P, Salomon A, Vodicska B, Servois V, Varkondi E, Gentien D, Tihanyi D, Tresca P, Lakatos D, Servant N, Deri J, du Rusquec P, Hegedus C, Bello Roufai D, Schwab R, Dupain C, Valyi-Nagy IT, Le Tourneau C. Petak I, et al. Among authors: hegedus c. NPJ Precis Oncol. 2021 Jun 23;5(1):59. doi: 10.1038/s41698-021-00191-2. NPJ Precis Oncol. 2021. PMID: 34162980 Free PMC article.
Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
Urbán L, Dóczi R, Vodicska B, Tihanyi D, Horváth M, Kormos D, Takács I, Pápai-Székely Z, Póka-Farkas Z, Várkondi E, Schwáb R, Hegedüs C, Vályi-Nagy I, Peták I. Urbán L, et al. Among authors: hegedus c. Clin Lung Cancer. 2021 Jan;22(1):e112-e115. doi: 10.1016/j.cllc.2020.09.005. Epub 2020 Sep 18. Clin Lung Cancer. 2021. PMID: 33082101 No abstract available.
Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
Brózik A, Hegedüs C, Erdei Z, Hegedus T, Özvegy-Laczka C, Szakács G, Sarkadi B. Brózik A, et al. Among authors: hegedus t, hegedus c. Expert Opin Drug Metab Toxicol. 2011 May;7(5):623-42. doi: 10.1517/17425255.2011.562892. Epub 2011 Mar 17. Expert Opin Drug Metab Toxicol. 2011. PMID: 21410427 Review.
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
Hegedüs C, Truta-Feles K, Antalffy G, Várady G, Német K, Ozvegy-Laczka C, Kéri G, Orfi L, Szakács G, Settleman J, Váradi A, Sarkadi B. Hegedüs C, et al. Biochem Pharmacol. 2012 Aug 1;84(3):260-7. doi: 10.1016/j.bcp.2012.04.010. Epub 2012 Apr 21. Biochem Pharmacol. 2012. PMID: 22548830
Lipid regulation of the ABCB1 and ABCG2 multidrug transporters.
Hegedüs C, Telbisz Á, Hegedűs T, Sarkadi B, Özvegy-Laczka C. Hegedüs C, et al. Among authors: hegedus t. Adv Cancer Res. 2015;125:97-137. doi: 10.1016/bs.acr.2014.10.004. Epub 2015 Jan 8. Adv Cancer Res. 2015. PMID: 25640268 Free article. Review.
183 results